Serina Therapeutics Balans Gezondheid
Financiële gezondheid criteriumcontroles 0/6
Serina Therapeutics has a total shareholder equity of $-16.4M and total debt of $11.1M, which brings its debt-to-equity ratio to -67.9%. Its total assets and total liabilities are $10.7M and $27.1M respectively.
Belangrijke informatie
-67.9%
Verhouding schuld/eigen vermogen
US$11.14m
Schuld
| Rente dekkingsratio | n/a |
| Contant | US$6.06m |
| Aandelen | -US$16.39m |
| Totaal verplichtingen | US$27.10m |
| Totaal activa | US$10.71m |
Recente financiële gezondheidsupdates
Geen updates
Recent updates
Analyse van de financiële positie
Kortlopende schulden: 2BO has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Langlopende schulden: 2BO has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Schuld/ eigen vermogen geschiedenis en analyse
Schuldniveau: 2BO has negative shareholder equity, which is a more serious situation than a high debt level.
Schuld verminderen: 2BO's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Balans
Analyse van de cashflow
Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.
Stabiele cash runway: 2BO has less than a year of cash runway based on its current free cash flow.
Voorspelling contante baan: 2BO has less than a year of cash runway if free cash flow continues to reduce at historical rates of 57.3% each year